Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

The FDA has ap­proved Gilead Sci­ences’ lenaca­pavir for HIV pre­ven­tion, mak­ing the high­ly-an­tic­i­pat­ed twice-year­ly shot avail­able to peo­ple in the US.

Lenaca­pavir was

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER